Characteristics | All | 1993–2003 | 2003–2010 | |||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Chemotherapy | ||||||
None | 236 | 56.3% | 95 | 58.3% | 141 | 55.1% |
Oral pyrimidine fluoride agents | 77 | 18.4% | 60 | 36.8% | 17 | 6.6% |
Anthracycline-based regimen | 26 | 6.2% | 3 | 1.8% | 23 | 9.0% |
Anthracycline plus taxane regimen | 54 | 12.9% | 3 | 1.8% | 51 | 19.9% |
Taxane-based regimen | 37 | 8.8% | 0 | 0.0% | 37 | 14.5% |
Trastuzumab | 23 | 5.5% | 2 | 1.2% | 21 | 8.2% |
Others | 4 | 1.0% | 1 | 0.6% | 3 | 1.2% |
Endocrine therapy | ||||||
None | 117 | 27.9% | 61 | 37.4% | 56 | 21.9% |
SERM or AI | 232 | 55.4% | 88 | 54.0% | 144 | 56.3% |
SERM + LHRHa | 61 | 14.6% | 13 | 8.0% | 48 | 18.8% |
Others | 9 | 2.1% | 1 | 0.6% | 8 | 3.1% |